论文部分内容阅读
目的探讨硝苯地平控释片联合缬沙坦治疗高血压合并2型糖尿病肾病患者的临床疗效。方法选取惠州市第一人民医院2016年1月至2017年2月收治的68例高血压合并2型糖尿病肾病患者作为研究对象,根据患者入院尾号奇偶数分为对照组(单用硝苯地平控释片)与观察组(硝苯地平控释片联合缬沙坦),每组34例。比较两组患者治疗前后尿素氮(BUN)、血肌酐(Scr)、血钾(K+)、24 h尿微量清蛋白排泄率(UAER)、收缩压(SBP)、舒张压(DBP)及不良反应发生情况。结果治疗后,观察组患者SBP、DBP及UAER水平均明显低于对照组,差异均有统计学意义(均P<0.05);观察组患者不良反应发生率明显低于对照组,差异有统计学意义(χ2=5.231,P<0.05)。结论针对高血压合并2型糖尿病肾病患者,采用硝苯地平控释片联合缬沙坦治疗能够有效改善患者临床症状,疗效显著、安全性高。
Objective To investigate the clinical efficacy of nifedipine controlled release tablets combined with valsartan in the treatment of patients with hypertension and type 2 diabetic nephropathy. Methods Sixty-eight hypertensive patients with type 2 diabetic nephropathy admitted from the First People’s Hospital of Huizhou from January 2016 to February 2017 were enrolled as study subjects, and were divided into control group (nifedipine Controlled release tablets) and observation group (nifedipine controlled release tablets combined with valsartan), 34 cases in each group. The levels of BUN, Scr, K +, 24 h urinary albumin excretion (UAER), systolic blood pressure (SBP), diastolic blood pressure (DBP) and adverse reactions were compared between the two groups before and after treatment What happened? Results After treatment, the levels of SBP, DBP and UAER in the observation group were significantly lower than those in the control group (all P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group Significance (χ2 = 5.231, P <0.05). Conclusion For patients with hypertension and type 2 diabetic nephropathy, the use of nifedipine controlled release tablets combined with valsartan can effectively improve the clinical symptoms of patients with significant curative effect and high safety.